A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

NCT05362110 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

361

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: HCP1803-3
DRUG: RLD2002
DRUG: HPP2003-3
DRUG: HPP2004

Sponsor

Hanmi Pharmaceutical Company Limited